Ipamorelin

Growth Hormone / IGF-1 Axis
Phase 2
Investigational

Ipamorelin is a selective compound that triggers growth hormone release, originally developed by Novo Nordisk. It stimulates growth hormone without significantly affecting cortisol or prolactin levels. It has been studied in clinical trials for postoperative recovery.

Last updated February 22, 2026
46 PubMed-Verified Studies
Very Popular
Research-Driven Dosage Reports
RouteSubcutaneous (SC)
Dose100–300 mcg
Frequency1–3× daily
Duration8–12 weeks

Based on published research literature.

Verified sources for Ipamorelin

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChems10% off
View all vendor deals·Affiliate links. Commission at no extra cost.

Overview of Ipamorelin

Selectively activates ghrelin receptors to stimulate growth hormone release without significantly affecting cortisol or prolactin levels.

Growth hormone axis

Selectively binds and activates ghrelin receptor (GHS-R1a) in the pituitary, triggering GH release with high selectivity.

Produces dose-proportional increase in circulating GH levels, allowing for predictable dosing strategies.

Preserves natural pulsatile GH patterns due to short half-life (~2 hours), maintaining physiological rhythm.

Hormonal selectivity

Does not significantly increase cortisol, ACTH, or prolactin, a notable difference from other GHRPs.

Minimal appetite stimulation compared to other ghrelin mimetics, which is preferred for those not seeking appetite increase.

Synergy / stacking

Often combined with CJC-1295 or other GHRH analogs (proposed), amplifying GH response through complementary pathways

Read Full Ipamorelin Dosage Guide

Research-backed dosing protocols, timing, and administration details

Browse more in this category

Growth Hormone / IGF-1 Axis